文献速递银屑病与炎症性皮肤病

在联合王国,司库奇尤单抗较乌司奴单抗和依那西普显著减少银屑病相关工作障碍和间接成本

Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-07-15

本研究为CLEAR研究(司库奇尤单抗对比乌司奴单抗)工作障碍数据的事后分析,并应用于FIXTURE研究(司库奇尤单抗对比依那西普),评估联合王国银屑病患者的工作时间损失和间接成本。结果显示,第16周至52周,司库奇尤单抗较乌司奴单抗和依那西普显著降低工作障碍和相关间接成本。

要点

  • CLEAR研究中基线时452例(67%)患者在职。
  • 第16周,随着PASI应答水平升高,每周工作障碍百分比/平均损失小时数降低。
  • 司库奇尤单抗较乌司奴单抗和依那西普的加权平均每周/每年工作损失小时数显著更低。

核心结论

  • 在联合王国,第16周至52周,司库奇尤单抗较乌司奴单抗和依那西普显著减少银屑病相关工作障碍及相关间接成本。

研究设计与样本

  • CLEAR研究(司库奇尤单抗对比乌司奴单抗)工作障碍数据的事后分析,并应用于FIXTURE研究(司库奇尤单抗对比依那西普)。

主要发现

  • CLEAR研究中基线时452例患者(67%)在职。
  • 第16周,每周工作障碍百分比/平均损失小时数随PASI升高而降低:PASI<50为22.8%/7.60小时;PASI 50-74为13.3%/4.45小时;PASI 75-89为6.4%/2.14小时;PASI≥90为4.9%/1.65小时。
  • 司库奇尤单抗较乌司奴单抗的加权平均每周/每年工作损失小时数显著更低(1.96/102.51 vs 2.40/125.12;P=0.0006)。
  • 司库奇尤单抗较依那西普的加权平均每周/每年工作损失小时数显著更低(2.29/119.67 vs 3.59/187.17;P<0.0001)。
  • 司库奇尤单抗较乌司奴单抗平均每年间接成本节省355英镑,较依那西普节省1061英镑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into differential indirect cost savings is unknown. OBJECTIVE: To assess work hours lost and indirect costs associated with secukinumab versus ustekinumab and etanercept in the United Kingdom (UK). METHODS: This was a post hoc analysis of work impairment data collected in the CLEAR study (secukinumab vs. ustekinumab) and applied to the FIXTURE study (secukinumab vs. etanercept). Weighted weekly and annual average indirect costs per patient per treatment were calculated from (i) overall work impairment derived from Work Productivity and Activity Impairment data collected in CLEAR at 16 and 52 weeks by Psoriasis Area and Severity Index (PASI) response level; (ii) weekly/annual work productivity loss by PASI response level; (iii) weekly and annual indirect costs by PASI response level, based on hours of work productivity loss; and (iv) weighted average indirect costs for each treatment. In the primary analysis, work impairment data for employed patients in CLEAR at Week 16 were used to compare secukinumab and ustekinumab. Secondary analyses were conducted at different time points and with patient cohorts, including FIXTURE. RESULTS: In CLEAR, 452 patients (67%) were employed at baseline. At Week 16, percentages of weekly work impairment/mean hours lost decreased with higher PASI: PASI < 50: 22.8%/7.60 h; PASI 50-74: 13.3%/4.45 h; PASI 75-89: 6.4%/2.14 h; PASI ≥ 90: 4.9%/1.65 h. Weighted mean weekly/annual work hours lost were significantly lower for secukinumab than ustekinumab (1.96/102.51 vs. 2.40/125.12; P = 0.0006). Results were consistent for secukinumab versus etanercept (2.29/119.67 vs. 3.59/187.17; Ρ<0.0001). Average annual indirect cost savings with secukinumab were £355 vs. ustekinumab and £1061 versus etanercept. Results at 52 weeks were similar. CONCLUSIONS: Secukinumab significantly reduced work impairment and associated indirect costs of psoriasis compared with ustekinumab and etanercept at Week 16 through 52 in the United Kingdom.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Warren RB, Halliday A, Graham CN, et al. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018. PMID: 29846965. doi:10.1111/jdv.15094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。